Stoke Therapeutics Stock Slips as CEO Steps Down
1. Stoke CEO Dr. Edward Kaye resigns, interim CEO Ian Smith appointed. 2. Q4 revenue reached $22.61 million, exceeding analyst consensus greatly. 3. Company reported a smaller-than-expected loss of $0.18 per share. 4. Stoke has $246.7 million in cash, funding operations through mid-2028. 5. Shares fell nearly 3% but up over 40% in the last year.